Latest News Round-UpChemical temperature indicators in transport of biologicsThe transportation of temperature-sensitive products has always been a significant challengefor the pharmaceutical and biotech industries to overcome. With the globalisation ofoperations, the problems faced by manufacturers are considerable when attempting tomaintain quality and reduce costs through careful cold chain management. According to onecompany, chemical temperature indicators – used mainly for vaccines in World HealthOrganization (WHO) initiatives – could have wider applications in several areas of business.Chemical indicators have been used as vaccine vial monitors (VVMs) in global immunisationschemes for a number of years, but according to one provider, their properties could be put towider use across the pharmaceutical industry. This could potentially ease somemanufacturers worries about cold chain product integrity, such as the concerns raised in aHarris Interactive Research survey conducted among US physicians last year.To access this complimentary article in full please click here: http://bit.ly/eKGVGuTransportation & Transfer of Biologics and Biological Agents 2011 will be hosted from 27th –29th April in San Francisco, California. For more details, please visit the website:www.transportbiologics.com, call freephone: 0800 652 2363 or email: firstname.lastname@example.org.New understanding of drug transport for primary immunodeficiencyKnowledge of the clinical implications surrounding subcutaneous (SC) dosing ofimmunoglobulin G (IgG) in primary immunodeficiency (PI) patients is somewhat limited. But arecent study has provided insight into how SC IgG is transported after injection, which couldsignificantly boost understanding of how it should be administered for optimal efficacy in thefuture.In March 2011, CSL Behring announced the development of an innovative newpharmacokinetic (PK) model, allowing the absorption, distribution, metabolism and excretion(ADME) of SC IgG to be simulated with a considerable degree of precision and accuracy. Thenew PK concept provides researchers with a means of imitating the mechanism throughwhich SC IgG is transported after being injected into the tissue.To access this complimentary article in full please click here: http://bit.ly/eKGVGuClinically Relevant Drug Transporters will be hosted from 12th – 14th April 2011 in Berlin,Germany. For more details, please visit the website: www.drug-transporters.com, callfreephone: 0800 652 2363 or email: email@example.com.__________________________________________________________________________Transporter experiments paving the way for new therapiesA testing methodology established recently by scientists in the US has enabled researchers tofurther their understanding of how the serotonin transporter contributes to clinically relevant,delayed effects of common antidepressant medicines. At a time when pharmaceuticalcompanies increasingly need to sharpen up their product development by applying effectivetesting and modeling practices, this could provide valuable insights.
The most widely-distributed antidepressants, names which include Prozac, Paxil andLexapro, work by blocking the serotonin transporter. Current thinking notes that this brainprotein normally clears away the mood-regulating chemical. But those theories about howselective serotonin reuptake inhibitors (SSRIs) operate can now be scrutinised through a newmouse model engineered by scientists at Vanderbilt University, Tennessee.__________________________________________________________________________To access this complimentary article in full, please click here: http://bit.ly/eKGVGuClinically Relevant Drug Transporters 2011 will be hosted from 12th – 14th April 2011 in Berlin,Germany. For more details, please visit the website: www.drug-transporters.com, callfreephone: 0800 652 2363 or email: firstname.lastname@example.org.__________________________________________________________________________Stamping out counterfeit drugs in Europe and USAs an ever-growing number of global clinical trials use comparator agents as a basis forinvestigation, pharmaceutical manufacturers increasingly need to ensure that a reliable andsecure sourcing strategy is in place throughout. Obtaining the right comparator drug is a taskfraught with all kinds of risks, particularly where security of supply chains is an issue. Thenumber of counterfeit drugs entering distribution channels is still on the rise, but authorities inEurope and the US have recently taken measures to tighten up the law.In February, a new law to prevent spurious medicines from entering the supply chain wasapproved by the European Parliament. The legislation extends to cover internet sales andintroduces several new safety and traceability measures. It could also see more severepenalties imposed on those found to be producing counterfeit drugs. The directive had beenin the legislative pipeline for more than two years and is designed to combat the estimatedone in 100 pharmaceutical products currently sold in the European Union (EU) through legalsupply chains that are actually counterfeit.To access this complimentary article in full, please click here: http://bit.ly/dSdDhOGlobal Comparator Studies 2011 will be hosted from 29th – 30th June in London, UK. For moredetails, please visit the website: www.globalcomparator.com, call freephone: 0800 652 2363or email: email@example.com.Are pharmaceutical supply chains due an outsourcing overhaul?The manufacturing and distribution dealings of drugmakers across the globe may beinefficient, under-utilised and ill-equipped to cope with the future challenges facingpharmaceuticals worldwide.Research published by PricewaterhouseCoopers (PwC) in February warned that the existinginfrastructure of many pharma firms was not sufficient to cope with new medicines, costpressures and health reform expectations.In recent years, drug companies have responded to industry upheaval by striving to discover,develop and market their medicines more efficiently, but many have failed to invest a lot oftime in reconfiguring the manufacturing and distribution sides of their business.To access this complimentary article in full please click here:www.gpcmevent.com/mediaGlobal Pharmaceutical Contract Manufacturing 2011 will be hosted from 27 - 29 June, 2011at the America Square Conference Centre, London, UK. For more details, please visit thewebsite: www.gpcmevent.com, call freephone: 0800 652 2363 or email: firstname.lastname@example.org.__________________________________________________________________________